Drug Profile
Metformin glycinate - Laboratorios Silanes
Alternative Names: DDMET-01; Metformin glycinateLatest Information Update: 28 Nov 2022
Price :
$50
*
At a glance
- Originator Laboratorios Silanes
- Class Antihyperglycaemics; Biguanides; Eye disorder therapies; Small molecules
- Mechanism of Action AMP activated protein kinase stimulants; Gluconeogenesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III SARS-CoV-2 acute respiratory disease; Type 2 diabetes mellitus
Most Recent Events
- 28 Nov 2022 Metformin glycinate is still in the phase III DMMETCOV19-2 trial for SARS-COV-2 acute respiratory disease in Mexico (PO) (NCT04625985)
- 08 Apr 2021 Laboratorios Silanes withdraws the phase II DMMETCOV19 trial prior to enrolment for Type 2 diabetes mellitus, Metabolic syndrome and SARS-COV-2 acute respiratory disease in Mexico (PO) due to company administrative decision (NCT04626089)
- 18 Mar 2021 Laboratorios Silanes completes the phase III DMMETCOV19-2 trial in SARS-COV-2 acute respiratory disease in Mexico (PO) (NCT04625985)